EUVIMEDEUVIMED entdecken
Crossref

Neuroinflammation through the vagus nerve-dependent gut–microbiota–brain axis in treatment-resistant depression

Kenji Hashimoto

Progress in Brain Research · 2023

DOI: 10.1016/bs.pbr.2023.01.003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Progress in Brain Research, 2023. Verfasst von Kenji Hashimoto. Beteiligte Einrichtung: Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, Chiba, Japan. Electronic address: hashimoto@faculty.chiba-u.jp. Hauptthemen laut MEDLINE: Major Depressive Disorder, Microbiota. Die Arbeit wurde bisher 50-mal zitiert (Crossref) und nennt 90 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neuroinflammation plays a key role in the pathogenesis of major depressive disorder (MDD), including treatment-resistant depression (TRD). Patients with TRD have higher levels of inflammatory biomarkers compared with responders to antidepressants. Multiple lines of evidence suggest that the gut-microbiota-brain axis via the vagus nerve plays a key role in neuroinflammation. Preclinical and clinical data suggest that fecal microbiota transplantation (FMT) from MDD patients or rodents with depression-like behaviors cause depression-like behaviors in rodents through systemic inflammation. Importantly, subdiaphragmatic vagotomy blocked these depression-like phenotypes and systemic inflammation in rodents after FMT of depression-related microbes. Subdiaphragmatic vagotomy also blocked the antidepressant-like effects of serotonergic antidepressants in rodents. Preclinical findings suggest that the new antidepressant, (R)-ketamine (or arketamine), may restore the altered composition of gut microbiota in rodents with depression-like behaviors, contributing to the beneficial effects of arketamine. In this chapter, the author reviews the role of the vagus nerve-dependent gut-microbiota-brain axis in depression (including TRD), and also discuss the potential of FMT, vagus nerve stimulation, and arketamine for the treatment of TRD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Major Depressive DisorderMicrobiotaHumansDepressionNeuroinflammatory DiseasesAntidepressive AgentsInflammationVagus NerveBrain

Stichwörter der Autor:innen

ArketamineDepressionFecal microbiota transplantationGut microbiotaKetamineNeurogenesisVagus nerveVagus nerve stimulation

Substanzen

Antidepressive Agents

Autor:innen und Institutionen

  • Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, Chiba, Japan. Electronic address: hashimoto@faculty.chiba-u.jp.

Förderung

  • Japan Society for the Promotion of Science

Zitieren

APA

Hashimoto, K. (2023). Neuroinflammation through the vagus nerve-dependent gut–microbiota–brain axis in treatment-resistant depression. Progress in Brain Research. https://doi.org/10.1016/bs.pbr.2023.01.003

Vancouver

Hashimoto K. Neuroinflammation through the vagus nerve-dependent gut–microbiota–brain axis in treatment-resistant depression. Progress in Brain Research. 2023. doi:10.1016/bs.pbr.2023.01.003

BibTeX
@article{Hashimoto2023,
  author = {Hashimoto, Kenji},
  title = {Neuroinflammation through the vagus nerve-dependent gut–microbiota–brain axis in treatment-resistant depression},
  journal = {Progress in Brain Research},
  year = {2023},
  doi = {10.1016/bs.pbr.2023.01.003}
}
Kostenlos starten →